Articles & videos

TargTex CEO João Seixas discusses the value Nanoform’s CESS technology delivered for TargTex’s novel drug candidate targeting glioblastoma, one of the most common and aggressive types of primary brain tumor. The partnership with Nanoform was critical in achieving success at this stage, with hope the product can now be taken further into clinical development.

Video 1: “Are you in or out?” panel discussion at Pharma Integrates 2021

Our VP of Business Development, Nathalie Huther, PhD, MRSC, shared her insights into how the pandemic has affected pharma outsourcing and what it means for the future at Pharma Integrates 2021.

Video 2: ’Forecasting Pharma’s Future” panel discussion at Pharma Integrates 2021

Our Commercial Insight Officer, Jamie Unwin, shared his perspective on the future of Pharma and patient-centric technological innovation at Pharma Integrates 2021.

Video 1: Nanotechnology Fireside Chat at Partnerships in Drug Delivery (PODD) 2021

Our CEO, Prof. Edward Hæggström, was delighted to join a fireside chat at PODD with Shawn Davies, Head of Drug Delivery, Biopharmaceuticals Development, AstraZeneca – a long term partner of Nanoform – to discuss the potential of nanoscale medicines and delivery devices to benefit patients.

Video 2: “Small is transformative: nanoparticle solutions for drug delivery innovation” at Partnerships in Drug Delivery (PODD) 2021

Our VP of US Business Development, Eric Peter, delved into the human trial results for the world’s first nanoformed drug at PODD 2021. He also discussed the ongoing industry collaborations investigating how nanoparticle engineering can facilitate drug delivery innovation to ultimately benefit patients.

Our Commercial Insights Officer, Jamie Unwin, sat down with Tim Pang, Executive Director, Pharma Consulting at Informa Pharma Custom Intelligence, at BIO-Europe 2021 for a fireside chat “(b)(2) or not to be – understanding the commercial returns possible from patient-centric differentiation strategies through the 505(b)(2) pathway.”

Our VP of US Business Development, Chris Worrall, hosted a webinar “Tailored API Nanoparticles: How Powerful Can Small Be?” in partnership with the American Association of Pharmaceutical Scientists (AAPS). Tune in to discover the benefits of tailoring nanoparticles for the development of patient-centric medicines.

Nanoform Director of Pharmaceutical Development, Satu Lakio, presented a poster to AAPS on the effectiveness of Nanoformed particles compared clinically against two commercially approved products.

Watch Nanoform Director of Pharmaceutical Development, Satu Lakio, present to AAPS how effective Nanoformed particles could be when compared clinically against two commercially approved products.

Nanoform were attendees at Life Science Integrates’ and the Medicines Manufacturing Innovation Centre’s one-day event, PharmaTech Integrates. Science & Technology Team Leader, Elisabetta Micelotta, hosted the technical showcase “Nanoformers, Particles in Disguise! – Illuminating the future of Pharma with STARMAP®.” In this session, she discussed the power of AI for streamlining drug development.

Nanoform were attendees at Life Science Integrates’ and the Medicines Manufacturing Innovation Centre’s one-day event, PharmaTech Integrates. Our Commercial Insights Officer, Jamie Unwin shared his thoughts on the “Revolution not evolution of Biologics production” panel. The session explored how the industry can step up to meet patient need and market demand by streamlining, enhancing and integrating upstream and downstream biological and vaccine production.

David McCelland from Life Science Knowledge Hub interviews Jamie Unwin, our Commercial Insights Officer at Nanoform. They discuss Nanoform’s growth and their ambition of touching the lives of billion patients. Jamie also emphasises the importance of their data-driven approach and how AI is transforming the approach to drug development.

The Nanoform team attended the American DDF Summit (Drug Delivery & Formulation) with Commercial Insights Officer Jamie Unwin chairing a panel discussion titled “Preparing for Patient-Centric Drug Development Regulations”. The session explored the topic of patient centric drug design and how patient centricity can influence the drug development process.

A year on from Nanoform’s IPO in June 2020, we have made trailblazing progress. In this video, we share how we’ve transformed to reach key milestones, from the launch of our biologics technology to the completion of our first-in-human trial of a nanoformed drug candidate.

We were pleased to host a session, “Overcoming Drug Development Challenges with Nanotechnology,” at the first ever CPhI Discover virtual event. Nanoform CCO Christian Jones, FRSC, Nanoform Science & Technology Team Leader Elisabetta Micelotta, and experts from Johnson Matthey and Quotient Sciences shared insights into the power of sparse-data AI in drug development and the collaborative studies investigating the performance of our CESS® technology.

Watch it here to learn more about AI-guided nanoparticle engineering in Pharma, from early drug development to clinic.

Our CCO, Christian Jones, FRSC, joined the Bio Integrates panel discussion “Start with an end in mind” on Thursday, May 20th, 2021. The panel explored the importance of connecting with patients to make sure that  products are designed around the patient’s needs.



We were excited to showcase the results from our collaboration with Johnson Matthey in our webinar with The Nanomed Zone: “How CESS® technology stacks up against the competition: the smaller, the better!”.

Watch the presentation to learn how CESS® nanoparticles of a model compound have been found to exhibit improved dissolution performance relative to all other industry standard approaches tested, including spray drying.



Our Director of Pharmaceutical Development, Satu Lakio, gave a presentation at the 12th Global DDF Summit (Drug Delivery & Formulation) covering “Unique Nanoforming Technology for Poorly Soluble APIs by Nanoform”.

We achieved a number of milestones in 2020, check out the highlights here!

In partnership with Quotient Sciences, the healthy volunteers have been successfully dosed in the first ever phase 1 human trial of a nanoformed drug candidate.

Hosted by Ted Danson, this episode of Advancements aimed to enlighten the public on how Nanoform’s award-winning CESS® nanoparticle engineering technology can potentially double the number of drug candidates progressing into clinic, open up new drug delivery routes and improve the lives of patients worldwide.

Join a virtual tour of our Helsinki facility to meet our experts, get up close to our award-winning technology, and even participate in real-time questions and discussions.

Our CCO, Christian Jones, joins Dr. Sophia Ononye-Onyia on the Amplifying Scientific Innovation podcast to discuss his outlook on the life science industry and Nanoform’s unique focus on nanotechnology innovation.

Our CCO, Christian Jones, shares his thoughts at the DDF Summit on how our award-winning CESS® technology can change the future of medicine.

Our CCO, Christian Jones, joins The Medicine Maker to discuss the challenges that the drug discovery and development market face today, and how our nanoforming technology can help solve these issues and drive pharmaceutical efficiency.

Our CTO, Niklas Sandler, and Head of AI, Jukka Corander, were interviewed by Contract Pharma to discuss the application of AI for enhanced drug particle engineering.

At the Bio-Europe Spring meeting, our CCO, Christian Jones, discusses how we use physics to enhance drug discovery and development for our partners in the pharmaceutical industry.